Apraglutide is a Synthetic Peptide owned by VectivBio, and is involved in 10 clinical trials, of which 5 were completed, 4 are ongoing, and 1 is planned.
Apraglutide (FE-203799) acts as GLP-2 receptor agonist. The drug candidate elicits therapeutic intervention by activating GLP-2 receptor via activation of adenylate cyclase, and consequently restores the normal physiological function of GI tract affected by mucositis exhibiting intestine-trophic and intestine-protective activity.
The revenue for Apraglutide is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Apraglutide NPV Report.
Apraglutide (FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route as a powder and solution for solution for injection. The drug candidate is a long acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was under development for the treatment of chemotherapy-induced gastro-intestinal mucositis.
VectivBio is biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for for severe rare conditions with high unmet medical need. The company’s lead product candidate GLP-2, targeting short bowel syndrome. VectivBio is headquartered in Basel, Switzerland.
The operating loss of the company was US$86.7 million in FY2021, compared to an operating loss of US$57.3 million in FY2020. The net loss of the company was US$87 million in FY2021, compared to a net loss of US$59.9 million in FY2020.
Quick View – Apraglutide
|Highest Development Stage|